Latest Syk Stories

SOUTH SAN FRANCISCO, Calif., July 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at BMO Capital Markets 10th Annual Focus on Healthcare Conference in New York City on Thursday, August 5th at 2:15 p.m. EDT. To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website...

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial officer of Rigel, will present at three separate investor conferences in June. Details of each conference are as follows: Jefferies Global Life Sciences Conference New York City, NY June 10, 8:00 a.m. EST Speaker: James M. Gower...

SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that eleven presentations on preclinical studies of the company's product candidates will be given at the upcoming American Society of Hematology (ASH) Meeting and Exposition in New Orleans, Louisiana from December 5-8, 2009. Rigel's R788, an oral Syk kinase inhibitor, will be discussed in two oral presentations by collaborators about its activity in distinct B-cell...

SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will webcast its analyst briefing on October 20, 2009 from 4:00-5:00pm EDT in conjunction with the 73rd Annual Scientific Meeting of the American College of Rheumatology (ACR). Members of Rigel's senior management team along with the principal investigators for the recently completed Phase 2b clinical trials (TASKi2 and TASKi3) will provide an update on the...

Researchers say the findings suggest drug therapy targeted against the gene's protein may be riskyResearchers at Georgetown University Medical Center (GUMC) are voicing alarm that drugs to treat a wide variety of allergies, asthma and autoimmune diseases now in human clinical trials may errantly spur development of breast tumors.As the researchers report in the October 15 issue of PLoS ONE, the gene SYK and its protein product, Syk*, are crucial for prevention of breast cancer in the mice and...

Preclinical Rationale for Clinical Trial Presented at USCAP Meeting SOUTH SAN FRANCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the enrollment of the first patient in a Phase 2, multi-center clinical trial of R788 (fostamatinib disodium) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL). The clinical trial's primary objective is to assess the efficacy of R788, an orally bio-available Syk kinase...

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that data related to the Company's series of novel compounds that inhibit spleen tyrosine kinase (Syk) and its novel universal Factor Xa inhibitor antidote will be presented at the annual meeting of the American Society of Hematology (ASH) at the...

US-based biotechnology company ZaBeCor Pharmaceuticals has announced the formation of its new subsidiary Biothorpe Pharmaceuticals, a biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of cancer. Biothorpe's intellectual property portfolio includes the therapeutic use of siRNA and other oligonucleotides directed at Syk kinase. Biothorpe intends to license its intellectual property for the treatment of three cancers - acute...

ZaBeCor Pharmaceuticals ("ZaBeCor") announces today the formation of its new subsidiary Biothorpe Pharmaceuticals ("Biothorpe" or the "Company"), a biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of cancer. Recent studies in academia and in the biopharmaceutical industry indicate that Syk kinase is required for the proliferation of malignant cells in several cancers. Biothorpe's intellectual property portfolio includes...